DOCSLIB.ORG

Clarification of the Definition of Complete Response in Multiple

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Clarification of the Definition of Complete Response in Multiple Letters to the Editor 2416 9 Lacy MQ, Hogan WJ, Gertz MA, Dispenzieri A, Rajkumar SV, Hayman S et al. multiple myeloma: a retrospective review from a tertiary referral center. Bone Successful treatment of scleromyxedema with autologous peripheral blood stem Marrow Transplant 2013; 48: 1302–1307. cell transplantation. Arch Dermatol 2005; 141: 1277–1282. 11 D'Souza A, Lacy M, Gertz M, Kumar S, Buadi F, Hayman S et al. Long-term 10 Dispenzieri A, Seenithamby K, Lacy MQ, Kumar SK, Buadi FK, Hayman SR et al. outcomes after autologous stem cell transplantation for patients with POEMS Patients with immunoglobulin light chain amyloidosis undergoing autologous syndrome (osteosclerotic myeloma): a single-center experience. Blood 2012; 120: stem cell transplantation have superior outcomes compared with patients with 56–62. Clarification of the definition of complete response in multiple myeloma Leukemia (2015) 29, 2416–2417; doi:10.1038/leu.2015.290 Table 1. Clarification of the definition of complete response in multiple myeloma In 2006, the International Myeloma Working Group (IMWG) Response Response criteriaa 1,2 published uniform response criteria for multiple myeloma (MM). subcategory These criteria with a minor clarifications have been widely used to measure the effectiveness of myeloma therapy clinical trials.3 The Complete No evidence of initial monoclonal protein isotype(s) fi b development of effective monoclonal antibodies for the treatment response (CR) on immuno xation of the serum and urine of MM, such as elotuzumab and daratumumab have brought to our Disappearance of any soft tissue plasmacytomas ⩽ 5% plasma cells in bone marrow attention an urgent problem in which patients achieving complete response (CR) can be erroneously classified using the IMWG criteria. In some cases it is possible that the original M protein light-chain isotype is As currently written, CR in MM requires negative immunofixation for still detected on immunofixation but the accompanying heavy-chain monoclonal (M) protein in the serum and urine. The intended purpose component has disappeared; this would not be considered as a CR even of this requirement was to demonstrate that the M protein secreted by though the heavy-chain component is not detectable, since it is possible MMcellsisnolongerdetectable(Table1).Wearenowawarethatnew that the clone evolved to one that secreted only light chains. Thus, if a patient has IgA lambda myeloma, then to qualify as CR there should be no monoclonal antibodies developed for the treatment of MM (e.g., IgA detectable on serum or urine immunofixation; if free lambda is daratumumab and elotuzumab) interfere with the assay by immuno- detected without IgA, then it must be accompanied by a different heavy- fixation since they appear as M proteins on immunofixation. An chain isotype (IgG, IgM, etc). aModified from Durie et al.1bRequires two abnormal immunofixation result due to interference of the assay by a consecutive assessments to be carried out at anytime before the institution therapeutically administered M protein was not foreseen by us. of any new therapy. The purpose of this letter is to clarify that CR requires disappearance of the original M protein associated with MM on AUTHOR CONTRIBUTIONS immunofixation, and that the determination of CR is not affected by unrelated M proteins that are secondary to therapeutically BGMD, JFSM, JB and SVR reviewed the literature and wrote the administered monoclonal antibodies, biclonal gammopathy, or manuscript. All authors reviewed and approved the final manuscript. post-therapy/transplant monoclonal/oligoclonal reconstitution phenomenon. Thus, for example, if a patient with IgA kappa MM treated with a monoclonal antibody has disappearance of the CONFLICT OF INTEREST fi original M protein but has a positive immuno xation for IgG BGMD has been on the independent review committees for Onyx, Janssen and kappa, this finding will not negate the determination of CR. In this Takeda. JFSM has been on the advisory committees for Janssen, Bristol-Myers Squibb, case, the IgG kappa M protein will be considered as an artifact Sanofi, Millennium, Celgene, Novartis and Onyx. JB has received honoraria for from a therapeutically administered antibody (e.g., daratumumab lectures from Janssen and honoraria for advisory boards from Janssen and Bristol and elotuzumab are both IgG kappa monoclonal antibodies). Meyers Squibb. The remaining authors declare no conflict of interest. Therefore, in order to ensure accuracy, and to reflect the original intended meaning and definition, we have revised the BGM Durie1, JFS Miguel2, J Blade3 and SV Rajkumar4 on behalf of wording of the IMWG definition of CR (Table 1). This clarification is the International Myeloma Working Group critical to enable accurate assessment of CR in trials with 1Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA, USA; monoclonal antibodies in MM. We recognize that the clarification 2Clinica Universidad de Navarra, Centro de Investigacion Medica will still result in a modest underestimation of the true CR rate in Aplicada (CIMA), IDISNA, Pamplona, Spain; trials using monoclonal antibodies since it is impossible to 3Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i distinguish the therapeutic antibody from the patients’ M protein Sunyer (IDIBAPS), Barcelona, Spain and if they happen to be of the same heavy- and light-chain isotype. 4Division of Hematology, Mayo Clinic, Rochester, MN, USA Thus, further updates will be forthcoming once we have validated E-mail: [email protected] new assays that can distinguish the two with accuracy. In this regard, we are encouraged by data on a new daratumumab immunofixa- tion reflex assay, in which the binding of an anti-idiotypic antibody REFERENCES to daratumumab altered its electrophoretic migration and thus 1 Durie BGM, Harousseau J-L, Miguel JS, Blade J, Barlogie B, Anderson K et al. Interna- distinguished the therapeutically administered monoclonal antibody tional uniform response criteria for multiple myeloma. Leukemia 2006; 20:1467–1473. 4 from M protein secreted by MM cells. TheroleoftheHevylite(San 2 Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. Inter- Diego, CA, USA) assay (for lgA and IgG), which has a sensitivity level national uniform response criteria for multiple myeloma (corrigenda/erratum). typically seen with immunofixation, will also need to be studied. Leukemia 2007; 21: 1134. Accepted article preview online 21 October 2015; advance online publication, 13 November 2015 Leukemia (2015) 2402 – 2448 © 2015 Macmillan Publishers Limited Letters to the Editor 2417 3 Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R et al. 4 McCudden P, Axel A, Slaets D, Frans S, Bald J, Schecter JM et al. Assessing clinical Consensus recommendations for the uniform reporting of clinical trials: report response in multiple myeloma (MM) patients treated with monoclonal antibodies of the International Myeloma Workshop Consensus Panel 1. Blood 2011; 117: (mAbs): validation of a daratumumab IFE reflex assay to distinguish malignant 4691–4695. M-protein from therapeutic antibody. J Clin Oncol 2015; 33. (abstr 8590). Illness and artistic creativity (on the 70th anniversary of the death of Béla Bartók, composer, ethnomusicologist and leukemia patient) Leukemia (2015) 29, 2417–2418; doi:10.1038/leu.2015.221 The 26 September 2015 marks the 70th anniversary of the death of the Hungarian composer Béla Bartók, one of the most important composers of the 20th century, who became famous not only for his ethnomusicological studies recording the folk music of the Hungarian people, but also for his physical suffering due to several illnesses which, ultimately, caused his premature death. Béla Bartók was born in Hungary in 1881 and received first musical training on the piano from his mother. His musical talent was so remarkable that he was already composing at age 8 and he gave his first public appearance at age 10. He studied piano and composition at the Royal Academy of Music in Budapest from 1899 until 1903, and was inspired by many, but his music was genuinely Hungarian in style. Soon after leaving the academy, Béla Bartók and Zoltán Kodály, another Hungarian composer, began recording and analyzing folk Figure 1. The Hungarian composer, pianist and ethnomusicologist fi fi 1–4 Béla Bartók sitting at the piano in New York in an undated photo music, both as collectors and proli c scienti c investigators. (picture-alliance/dpa). This ethnomusicological research also heavily influenced Bartók’s own compositions. After meeting Claude Debussy, Bartók and in September for a long time. I feel the same now as I felt abandoned romanticism, adapted a more radical composing style fi ‘ ’ then. If I had stayed there, they would have molested me without and became one of the rst to write in a neo-classical manner any result until I would have got bored with it.’ In New York using some of the ancient scales from Hungarian folk music and financial hardship and disillusionment with world politics added to adopting a 12-tone scale enabling him to use various new Bartók’s state of poor health. He was no longer composing, as his harmonic combinations. spirit had been broken. On 20 June 1941 he wrote to his son: Owing to his vehement disapproval of the political change in ‘ fi I have become depressed by the frustrations I have encountered Hungary due to the nazi cation of Germany, Bartók and his wife ’ emigrated to the United States in 1940 (see Figure 1). In New York in personal and other matters . After receiving X-rays of his abdomen later that year Bartók Columbia University conferred the degree of Doctor of Music wrote: ‘... The doctor, the one who examined my ‘inwards’ in July, upon Bartók, where he transcribed and assembled Yugoslav folk songs and gave lectures, but his financial situation was insecure radiographs my left shoulder. The result is 00. But it is all the same, fi because I can play the piano, but I could do that before the X-ray and his deteriorating health was a detriment to his scienti c and ’ ’ musical activities.
Load more

Recommended publications
  • Lactoferrin and Its Detection Methods: a Review
    nutrients Review Lactoferrin and Its Detection Methods: A Review Yingqi Zhang, Chao Lu and Jin Zhang * Department of Chemical and Biochemical Engineering, University of Western Ontario, London, ON N6A 5B9, Canada; [email protected] (Y.Z.); [email protected] (C.L.) * Correspondence: [email protected] Abstract: Lactoferrin (LF) is one of the major functional proteins in maintaining human health due to its antioxidant, antibacterial, antiviral, and anti-inflammatory activities. Abnormal levels of LF in the human body are related to some serious diseases, such as inflammatory bowel disease, Alzheimer’s disease and dry eye disease. Recent studies indicate that LF can be used as a biomarker for diagnosis of these diseases. Many methods have been developed to detect the level of LF. In this review, the biofunctions of LF and its potential to work as a biomarker are introduced. In addition, the current methods of detecting lactoferrin have been presented and discussed. We hope that this review will inspire efforts in the development of new sensing systems for LF detection. Keywords: lactoferrin; biomarkers; immunoassay; instrumental analysis; sensor 1. Introduction Lactoferrin (known as lactotransferrin, LF), with a molecular weight of about 80 kDa, is a functional glycoprotein, which contains about 690 amino acid residues. It was first isolated from bovine milk by Sorensen in 1939 and was first isolated from human milk by Citation: Zhang, Y.; Lu, C.; Zhang, J. Johanson in 1960 [1,2]. The three-dimensional structure of LF has been unveiled by high Lactoferrin and Its Detection resolution X-ray crystallographic analysis, and it consists of two homologous globular lobes Methods: A Review.
    [Show full text]
  • Spontaneous Reversal of Acquired Autoimmune Dysfibrinogenemia Probably Due to an Antiidiotypic Antibody Directed to an Interspec
    Spontaneous reversal of acquired autoimmune dysfibrinogenemia probably due to an antiidiotypic antibody directed to an interspecies cross-reactive idiotype expressed on antifibrinogen antibodies. A Ruiz-Arguelles J Clin Invest. 1988;82(3):958-963. https://doi.org/10.1172/JCI113704. Research Article A young man with a long history of abnormal bleeding was seen in January 1985. Coagulation tests showed dysfibrinogenemia and an antifibrinogen autoantibody was demonstrable in his serum. This antibody, when purified, was capable of inhibiting the polymerization of normal fibrin monomers, apparently through binding to the alpha fibrinogen chain. 6 mo later the patient was asymptomatic, coagulation tests were normal, and the antifibrinogen autoantibody was barely detectable. At this time, affinity-purified autologous and rabbit antifibrinogen antibodies were capable of absorbing an IgG kappa antibody from the patient's serum, which reacted indistinctly with both autologous and xenogeneic antifibrinogen antibodies in enzyme immunoassays. It has been concluded that the patient's dysfibrinogenemia was the result of an antifibrinogen autoantibody, and that later on an anti-idiotype antibody, which binds an interspecies cross- reactive idiotype expressed on anti-human fibrinogen antibodies, inhibited the production of the antifibrinogen autoantibody which led to the remission of the disorder. Find the latest version: https://jci.me/113704/pdf Spontaneous Reversal of Acquired Autoimmune Dysfibrinogenemia Probably Due to an Antildiotypic Antibody Directed to an Interspecies Cross-reactive Idiotype Expressed on Antifibrinogen Antibodies Alejandro Ruiz-Arguelles Department ofImmunology, Laboratorios Clinicos de Puebla, Puebla, Puebla 72530, Mexico Abstract disorder. This anti-Id antibody was shown to react with xeno- geneic antifibrinogen antibodies, hence, its specificity is an A young man with a long history of abnormal bleeding was interspecies cross-reactive Id (IdX)' most likely encoded by seen in January 1985.
    [Show full text]
  • Guidelines for Writing Examination Items (Questions)
    Guidelines for Writing Examination Items (Questions) Enclosed are the content outlines for the Immunology certification examinations. The content outline specifies the breakdown of content and overall structure of the examination and indicates how many test questions are assigned to each topic area from a total of 70 questions. The content outline will guide you in creating new items to match certain topic areas. We would appreciate at least two (2) new items for each major roman numeral on the content outline(s). This means we are asking you to write two items for Roman numeral I, two items for Roman numeral II, and so on for each of the Roman numeral sections of the Content Outline. We would appreciate items submitted in advance, preferably no later than Tuesday, February 25, 2020. • Please use the “Item Writing Template” to create your new items. This is the proper format to be used for all items you submit. Font: Times New Roma. Font Size: 11 • Please identify the Content Outline position for each item (e.g., Chemistry Content Outline, Roman numeral I. “Proteins”, A. “Total Proteins” should be noted as “I.A.”). • New items must be multiple choice with four (4) possible answers. Remember to avoid "double negatives," "not" questions (e.g., "Which of the following is NOT true?"), and those allowing "all (or none) of the above," or "a and b" as a possible answer. • Each new item that you create must be accompanied with a reference [Author, Publication Year, Title, Edition, Page Number(s)] containing the correct answer. IMPORTANT: references must be from an AAB Review Manual, Governmental Regulations, Association or World Health Organization (WHO) Guidelines, or a text or manual published within the last six (6) years.
    [Show full text]
  • Monoclonal Antibody Playbook
    Federal Response to COVID-19: Monoclonal Antibody Clinical Implementation Guide Outpatient administration guide for healthcare providers 2 SEPTEMBER 2021 1 Introduction to COVID-19 Monoclonal Antibody Therapy 2 Overview of Emergency Use Authorizations 3 Site and Patient Logistics Site preparation Patient pathways to monoclonal administration 4 Team Roles and Responsibilities Leadership Administrative Clinical Table of 5 Monoclonal Antibody Indications and Administration Indications Contents Preparation Administration Response to adverse events 6 Supplies and Resources Infrastructure Administrative Patient Intake Administration 7 Examples: Sites of Administration and Staffing Patterns 8 Additional Resources 1 1. Introduction to Monoclonal Therapy 2 As of 08/13/21 Summary of COVID-19 Therapeutics 1 • No Illness . Health, no infections • Exposed Asymptomatic Infected . Scope of this Implementation Guide . Not hospitalized, no limitations . Monoclonal Antibodies for post-exposure prophylaxis (Casirivimab + Imdevimab (RGN)) – EUA Issued. • Early Symptomatic . Scope of this Implementation Guide . Not hospitalized, with limitations . Monoclonal Antibodies for treatment (EUA issued): Bamlanivimab + Etesevimab1 (Lilly) Casirivimab + Imdevimab (RGN) Sotrovimab (GSK/Vir) • Hospital Adminission. Treated with Remdesivir (FDA Approved) or Tocilizumab (EUA Issued) . Hospitalized, no acute medical problems . Hospitalized, not on oxygen . Hospitlaized, on oxygen • ICU Admission . Hospitalized, high flow oxygen, non-invasive ventilation
    [Show full text]
  • Ab200015 Human Lactoferrin Simplestep ELISA® Kit
    Version 1 Last updated 28 August 2019 ab200015 Human Lactoferrin SimpleStep ELISA® Kit For the quantitative measurement of Lactoferrin in human serum, plasma, milk, urine, saliva, and cell culture supernatants. This product is for research use only and is not intended for diagnostic use. Copyright © 2018 Abcam. All rights reserved Table of Contents 1. Overview 1 2. Protocol Summary 2 3. Precautions 3 4. Storage and Stability 3 5. Limitations 4 6. Materials Supplied 4 7. Materials Required, Not Supplied 5 8. Technical Hints 5 9. Reagent Preparation 7 10. Standard Preparation 8 11. Sample Preparation 9 12. Plate Preparation 11 13. Assay Procedure 12 14. Calculations 14 15. Typical Data 15 16. Typical Sample Values 16 17. Assay Specificity 23 18. Species Reactivity 23 19. Troubleshooting 24 20. Notes 25 Technical Support 26 Copyright © 2018 Abcam. All rights reserved 1. Overview Lactoferrin in vitro SimpleStep ELISA® (Enzyme-Linked Immunosorbent Assay) kit is designed for the quantitative measurement of Lactoferrin protein in humanserum, plasma, milk, urine, saliva, and cell culture supernatants. The SimpleStep ELISA® employs an affinity tag labeled capture antibody and a reporter conjugated detector antibody which immunocapture the sample analyte in solution. This entire complex (capture antibody/analyte/detector antibody) is in turn immobilized via immunoaffinity of an anti-tag antibody coating the well. To perform the assay, samples or standards are added to the wells, followed by the antibody mix. After incubation, the wells are washed to remove unbound material. TMB Development Solution is added and during incubation is catalyzed by HRP, generating blue coloration. This reaction is then stopped by addition of Stop Solution completing any color change from blue to yellow.
    [Show full text]
  • El Paso Community College Syllabus Part II Official Course Description
    MLAB 1235; Revised Fall 2019/Spring 2020 El Paso Community College Syllabus Part II Official Course Description SUBJECT AREA Medical Laboratory Technology COURSE RUBRIC AND NUMBER MLAB 1235 COURSE TITLE Immunology/Serology COURSE CREDIT HOURS 2 1 : 3 Credits Lec Lab I. Catalog Description Provides an introduction to the theory and application of basic immunology, including the immune response, principles of antigen-antibody reactions, and the principles of serological procedures as well as quality control, quality assurance, and lab safety. A grade of “C” or better is required in this course to take the next course. Corequisite: MLAB 1260. (1:3). Lab fee. II. Course Objectives A. Unit I. Laboratory Operations Upon satisfactory completion of this unit, the student will be able to: 1. Demonstrate adherence to Standard Precautions and the organizations’ SOP (Standard Operating Procedures) at all times. 2. Discuss legal and ethical concerns pertaining to Patient Informed Consent, Standard of Care, and HIPAA regulations. 3. Compliance with government, state, and organizational safety regulations involving Biological, Chemical, Radioactive, Fire, Physical, and Electrical hazards. 4. Explain the importance of actively participating in Quality Assurance, Quality Control and Proficiency Testing protocols incorporating precision, accuracy, Levi Jennings Charts and Westgard Rules. 5. Locate and make use of MSDS (Material Safety Data Sheets) 6. Discuss how OSHA affects safety, health, and compliance policies in the workplace. 7. Discuss nosocomial infections and identify the basic programs for infection control. 8. Identify the potential routes of infection and methods for preventing transmission of microorganisms through these routes. 9. Explain the proper techniques for hand washing, gowning, gloving, and masking.
    [Show full text]
  • Tests for Autoimmune Diseases Test Codes 249, 16814, 19946
    Tests for Autoimmune Diseases Test Codes 249, 16814, 19946 Frequently Asked Questions Panel components may be ordered separately. Please see the Quest Diagnostics Test Center for ordering information. 1. Q: What are autoimmune diseases? A: “Autoimmune disease” refers to a diverse group of disorders that involve almost every one of the body’s organs and systems. It encompasses diseases of the nervous, gastrointestinal, and endocrine systems, as well as skin and other connective tissues, eyes, blood, and blood vessels. In all of these autoimmune diseases, the underlying problem is “autoimmunity”—the body’s immune system becomes misdirected and attacks the very organs it was designed to protect. 2. Q: Why are autoimmune diseases challenging to diagnose? A: Diagnosis is challenging for several reasons: 1. Patients initially present with nonspecific symptoms such as fatigue, joint and muscle pain, fever, and/or weight change. 2. Symptoms often flare and remit. 3. Patients frequently have more than 1 autoimmune disease. According to a survey by the Autoimmune Diseases Association, it takes up to 4.6 years and nearly 5 doctors for a patient to receive a proper autoimmune disease diagnosis.1 3. Q: How common are autoimmune diseases? A: At least 30 million Americans suffer from 1 or more of the 80 plus autoimmune diseases. On average, autoimmune diseases strike three times more women than men. Certain ones have an even higher female:male ratio. Autoimmune diseases are one of the top 10 leading causes of death among women age 65 and under2 and represent the fourth-largest cause of disability among women in the United States.3 Women’s enhanced immune system increases resistance to infection, but also puts them at greater risk of developing autoimmune disease than men.
    [Show full text]
  • A Challenging Case of Igd Kappa Multiple Myeloma Associated with Primary Amyloidosis: Importance of Serum Free Light Chains in M
    L al of euk rn em u i o a J Journal of Leukemia García de Veas Silva JL et al, J Leuk 2014, 2:5 ISSN: 2329-6917 DOI: 10.4172/2329-6917.1000164 Case Report Open Access A Challenging Case of IgD Kappa Multiple Myeloma Associated With Primary Amyloidosis: Importance of Serum Free Light Chains in Monitoring Treatment Response and Disease Relapse José Luis García de Veas Silva1*, Carmen Bermudo Guitarte1, Paloma Menéndez Valladares1, Rafael Duro Millán2 and Johanna Carolina Rojas Noboa2 1Department of Clinical Biochemistry, Hospital Universitario Virgen Macarena, Sevilla, Spain 2Department of Hematology, Hospital Universitario Virgen Macarena, Sevilla, Spain *Corresponding author: José Luis García de Veas Silva, Laboratory of Proteins, Department of Clinical Biochemistry, Hospital Universitario Virgen Macarena, Sevilla, Spain, Tel: +034955008108; E-mail: [email protected] Rec date: Oct 10, 2014, Acc date: Oct 16, 2014; Pub date: Oct 24, 2014 Copyright: © 2014 García de Veas Silva JL, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Multiple Myeloma (MM) is a malignancy of B cells characterized by an atypical proliferation of plasma cells. IgD MM has a very low incidence (2% of total MM cases) and it´s characterized by an aggressive course and a worse prognosis than other subtypes. The serum free light chains (sFLC) are very important markers for monitoring patients with MM and other monoclonal gammopathies. When the sFLC are present in low concentrations, it is often difficult to detect them by conventional methods such as serum protein electrophoresis and serum immunofixation.
    [Show full text]
  • Understanding the Immune System: How It Works
    Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute NIH Publication No. 03-5423 September 2003 www.niaid.nih.gov www.nci.nih.gov Contents 1 Introduction 2 Self and Nonself 3 The Structure of the Immune System 7 Immune Cells and Their Products 19 Mounting an Immune Response 24 Immunity: Natural and Acquired 28 Disorders of the Immune System 34 Immunology and Transplants 36 Immunity and Cancer 39 The Immune System and the Nervous System 40 Frontiers in Immunology 45 Summary 47 Glossary Introduction he immune system is a network of Tcells, tissues*, and organs that work together to defend the body against attacks by “foreign” invaders. These are primarily microbes (germs)—tiny, infection-causing Bacteria: organisms such as bacteria, viruses, streptococci parasites, and fungi. Because the human body provides an ideal environment for many microbes, they try to break in. It is the immune system’s job to keep them out or, failing that, to seek out and destroy them. Virus: When the immune system hits the wrong herpes virus target or is crippled, however, it can unleash a torrent of diseases, including allergy, arthritis, or AIDS. The immune system is amazingly complex. It can recognize and remember millions of Parasite: different enemies, and it can produce schistosome secretions and cells to match up with and wipe out each one of them.
    [Show full text]
  • Datasheet: MCA2763 Product Details
    Datasheet: MCA2763 Description: MOUSE ANTI HUMAN LACTOFERRIN Specificity: LACTOFERRIN Format: Purified Product Type: Monoclonal Antibody Clone: 2B8 Isotype: IgG1 Quantity: 0.2 mg Product Details Applications This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols. Yes No Not Determined Suggested Dilution Flow Cytometry Immunohistology - Frozen Immunohistology - Paraffin ELISA Immunoprecipitation Western Blotting Functional Assays Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using the appropriate negative/positive controls. Target Species Human Product Form Purified IgG - liquid Preparation Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant Buffer Solution Phosphate buffered saline Preservative 0.09% Sodium Azide (NaN ) Stabilisers 3 Approx. Protein 1.0mg/ml Concentrations Immunogen Purified Lactoferrin from human milk. External Database UniProt: Links P02788 Related reagents Page 1 of 3 Entrez Gene: 4057 LTF Related reagents Synonyms LF Fusion Partners Spleen cells from immunised Balb/c mice were fused with cells of the Sp2/0 myeloma cell line. Specificity Mouse anti Human Lactoferrin antibody, clone 2B8 recognizes human lactoferrin, a ~80 kDa globular iron binding glycoprotein found in body secretions such as milk and saliva and is a member of the transferrin family proteins.
    [Show full text]
  • Coverage of Monoclonal Antibody Products to Treat COVID-19
    Coverage of Monoclonal Antibody Products to Treat COVID-19 Monoclonal antibody products to treat Coronavirus disease 2019 (COVID-19) help the body fight the virus or slow the virus’s growth. Medicare beneficiaries have coverage without beneficiary cost sharing for these products when used as authorized or approved by the Food and Drug Administration (FDA). Disclaimer: The contents of this document do not have the force and effect of law and are not meant to bind the public Medicare in any way, unless specifically incorporated into a contract. This document is intended only to provide clarity to the public regarding existing requirements under the law. This communication was printed, published, or produced and disseminated at U.S. taxpayer expense. Site of Care1 Payable by Expected Patient Expected Payment to Providers: Medicare Cost-Sharing Key Facts • Medicare payment for monoclonal antibody products to treat COVID-19 is similar across Inpatient No patient sites of care, with some small differences. Hospital cost-sharing • Medicare pays for the administration of monoclonal antibody products to treat COVID-19. For example, beginning on May 6, 2021, Medicare will pay approximately Outpatient $450 in most settings, or approximately $750 No patient in the beneficiary’s home or residence, for Hospital or cost-sharing the administration of certain monoclonal “Hospital 4 2 antibody products to treat COVID-19. For without Walls ” monoclonal antibody products to treat COVID-19 that are administered before May 6, 2021, the Medicare payment rate in all No patient settings is approximately $310. Outpatient cost-sharing3 Physician Office/ • CMS will exercise enforcement discretion to Infusion Center allow Medicare-enrolled immunizers working within their scope of practice and subject to applicable state law to bill directly and receive direct reimbursement from the Medicare program for administering Nursing Home monoclonal antibody treatments to No patient (See third bullet in Medicare Part A Skilled Nursing Facility Key Facts on CMS cost-sharing residents.
    [Show full text]
  • Monoclonal Antibody Treatment for COVID-19
    Monoclonal Antibody Treatment for COVID-19 Monoclonal antibody treatment is for people who have COVID-19 or were recently exposed to someone who has COVID-19, and are not hospitalized. Treatment can lower the amount of virus in your body, reduce symptoms and help avoid hospitalization. Treatment works best when you get it soon after COVID-19 symptoms begin, so it is important to get tested right away. What is monoclonal antibody treatment? How is monoclonal antibody Monoclonal antibodies are made in a lab and treatment given? work similarly to antibodies your immune Treatment is usually given by intravenous (IV) system makes to fight infection. Monoclonal infusion and takes about an hour. Treatment can antibody treatment helps your body fight also be given by injection. Patients are observed COVID-19 while your immune system begins for an additional hour to make sure they do not to make its own antibodies. In clinical studies, have any immediate bad reactions. monoclonal antibody treatments were shown to be safe and effective. What are the side effects? Side effects may include: Who is eligible for monoclonal antibody treatment? • A reaction at the site of the IV or injection, including pain, swelling, bleeding or bruising Treatment is authorized for people who meet all the following: • Nausea, vomiting or diarrhea • Itching, rash or hives Tested positive for COVID-19 Have had mild to moderate COVID-19 Allergic reactions and other serious side effects symptoms for 10 days or less are very rare. If you experience fever, trouble breathing, rapid or slow heart rate, tiredness, Are age 12 or older and weigh at least 88 pounds weakness, confusion, or other concerning symptoms, contact your provider right away.
    [Show full text]